GT Biopharma | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.14 21:04
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.83, missing the estimate of USD -0.38.

EBIT: As of FY2025 Q3, the actual value is USD -3.418 M.

Segment Revenue

  • GT Biopharma, Inc. did not report any revenue for the three and nine months ended September 30, 2025 and 2024.

Operational Metrics

  • Net Loss: The net loss for the three months ended September 30, 2025, was $3,114,000, a decrease from $3,411,000 in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $5,323,000, compared to $9,387,000 in 2024.
  • Research and Development Expenses: Decreased by $673,000 (51%) for the three months and $1,772,000 (46%) for the nine months ended September 30, 2025, compared to the same periods in 2024.
  • Selling, General, and Administrative Expenses: Increased by $72,000 (3%) for the three months but decreased by $2,166,000 (33%) for the nine months ended September 30, 2025, compared to the same periods in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was $8,893,000, compared to $10,436,000 in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided was $7,470,000, compared to $2,976,000 in 2024.

Unique Metrics

  • Warrant Liability: The change in fair value of warrant liability resulted in an increase of $137,000 for the three months ended September 30, 2025, compared to the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: GT Biopharma, Inc. is advancing its GTB-3650 product candidate through clinical studies, with enrollment starting in January 2025. The company plans to submit an IND application for GTB-5550 by late December 2025 or January 2026.
  • Non-Core Business: The company is exploring potential manufacturers for GTB-7550, a product candidate for lupus and other autoimmune disorders.
  • Priority: The company emphasizes the development of its TriKE® platform, aiming to bring immuno-oncology products to market for treating hematologic malignancies, solid tumors, and potentially autoimmune disorders.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.